Reversibility of the interaction of CGP 11305 A with MAO A in vivo
- 1 October 1983
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 94 (1-2) , 101-108
- https://doi.org/10.1016/0014-2999(83)90446-6
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- The monoamine oxidase inhibiting properties of CGP 11305 AEuropean Journal of Pharmacology, 1983
- The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargylineBiochemical Pharmacology, 1982
- A new approach to the assessment of the potency of reversible monoamine oxidase inhibitors in vivo, and its application to (+)- amphetamine, p-methoxy amphetamine and harmalineBiochemical Pharmacology, 1980
- A METHOD FOR THE ASSAY OF CONJUGATED 3,4‐DIHYDROXYPHENYLGLYCOL, A MAJOR NORADRENALINE METABOLITE IN THE RAT BRAINJournal of Neurochemistry, 1976
- Turnover of acid dopamine metabolites in striatal and mesolimbic tissue of the rat brainEuropean Journal of Pharmacology, 1976
- Preferential deamination of dopamine by an A type monoamine oxidase in rat brainNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1976
- The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formationEuropean Journal of Pharmacology, 1975
- A sensitive and specific assay for the estimation of monoamine oxidaseBiochemical Pharmacology, 1963